For the allogenic setting some trials report no impact of donor CHIP on recipient survival, disease progression and transplantation-related complications (22), whereas other studies report e.g., higher incidences of acute or chronic graft-versus-host disease in the presence of donor CHIP (23–25). This evidence concerns the gene STUB1 and chronic graft versus host disease.